Mycozol

Quick links to important sections

Mycozol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mycozol

Property Description
Active Ingredients Miconazole, Thiabendazole, Salicylic Acid, Benzoic Acid
Form Topical Preparation (e.g., cream, ointment, or solution)
Pharmacological Class Topical Antifungal and Keratolytic Agent
Common Use Managing superficial fungal and microbial skin conditions
Origin Synthetic Combination Drug Product

Mycozol: Definition, Type, and Class

Mycozol is a synthetic, combination drug product classified pharmacologically as a broad-spectrum Topical Antifungal, which also possesses Keratolytic Agent properties. This medicine is designed exclusively for topical (dermal) application as a suitable topical preparation. The medicine's identity is defined by its integrated approach, which combines several distinct agents to address both the microbial cause of infection and the associated skin damage. This four-ingredient composition differentiates it from common simpler single- or dual-agent preparations.


Composition and Synergistic Active Ingredients

The core composition of Mycozol consists of four active ingredients: Miconazole, Thiabendazole, Salicylic Acid, and Benzoic Acid. This comprehensive formula utilizes a synergistic strategy, integrating both direct microbial control and active skin management. Miconazole is an azole antifungal, while Thiabendazole is a benzimidazole derivative offering additional antifungal action. The non-antifungal agents include Salicylic Acid, a recognized keratolytic drug, and Benzoic Acid, which contributes generalized antimicrobial properties. These ingredients are incorporated into an appropriate emollient base that ensures uniform delivery to the superficial layers of the skin.


General Purpose: What is Mycozol Used for at a High Level?

Mycozol’s general purpose is to manage and promote the resolution of superficial fungal skin conditions by leveraging the combined effect of its four active ingredients. The formula is specifically engineered for skin conditions often characterized by significant scaling or thickening (hyperkeratosis). The integrated design provides a synergistic action: the primary antifungal ingredients address the microbial cause, while the keratolytic component aids in the shedding of infected skin tissue, helping to clear the area for healing. The use of such combinations is a therapeutic strategy to address both infection and associated symptoms.

What side effects are possible with Mycozol?

The official safety profile for Mycozol, a topical preparation combining Miconazole, Thiabendazole, Salicylic Acid, and Benzoic Acid, is documented in regulatory sources based on the adverse reactions and constraints of its active components.

Documented Adverse Reactions

Adverse effects are often classified as Uncommon or Not Known (cannot be estimated from available data) and primarily involve the Skin and Subcutaneous Tissue Disorders or General Disorders and Administration Site Conditions.

  • Uncommon Reactions: These include skin burning sensation, skin inflammation, skin hypopigmentation, and localized application site reactions such as irritation, burning, pruritus, and warmth.
  • Reactions of Not Known Frequency: Documented post-marketing experience lists hypersensitivity, contact dermatitis, rash, erythema, pruritus, angioedema, and anaphylactic reaction.

Serious Adverse Reactions and Systemic Risks

Regulatory documentation notes the potential for serious adverse reactions, including Anaphylactic reaction and Angioedema, particularly associated with the drug class. The product carries a risk of systemic toxicity, known as Salicylism, from the Salicylic Acid component, which is a concern with prolonged use over large areas or in individuals with reduced renal or hepatic function.

Population-Specific Safety Notes

Official labeling includes specific constraints for certain populations. The product is not to be used in children or teenagers experiencing varicella or influenza due to the increased risk of Reye's syndrome from the salicylate component. The use of salicylates is limited during pregnancy, with avoidance advised in the third trimester. Caution is also noted for nursing mothers.

Regulatory Restrictions

High-level safety constraints include a contraindication for individuals with known hypersensitivity to any active substance. Use must be restricted to prevent contact with the eyes, lips, and all mucous membranes. Caution is also advised regarding the potential for enhanced effects of oral anticoagulants (such as Warfarin).

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The information below is based strictly on descriptions of overdose and mandated actions found in government regulatory labeling for the active components of Mycozol (Miconazole, Thiabendazole, Salicylic Acid, and Benzoic Acid).


Documented Overdose Manifestations

Systemic overdose, primarily due to accidental oral ingestion or extensive topical absorption, may present with signs of Salicylate Toxicity (Salicylism). Officially documented symptoms include tinnitus (ringing in the ears), dizziness, headache, nausea, and vomiting. Severe or life-threatening manifestations listed in regulatory documents include metabolic acidosis, profound central nervous system (CNS) depression, and hyperpyrexia.


Required Emergency Actions

The regulatory labeling mandates that a patient seek immediate medical attention upon suspected overdose or accidental ingestion. Immediate contact with a Poison Control Center is required for guidance. Since no specific antidote is known, the management of overdose is defined as symptomatic and supportive treatment, including the correction of acid-base imbalances and monitoring of fluid and electrolyte status.


Monitoring and Population Considerations

Hospital monitoring is required for systemic overdose, including serial laboratory assessment of serum salicylate levels and acid-base status. Regulatory documents note that pediatric patients and individuals with pre-existing renal or hepatic impairment may be at increased risk for toxicity and severe outcomes.

Therapeutic Uses of Mycozol

Quick Facts: Mycozol

  • Therapeutic Domain: Management of specific fungal infections.
  • Primary Uses: Addresses candidiasis affecting the oral cavity and throat (oropharyngeal candidiasis).
  • Additional Use: Used in the management of vulvovaginal candidiasis.

What Mycozol Treats: Main Uses and Benefits

Mycozol is a medication used in the management of infections caused by certain types of fungi. Its therapeutic domain is focused on reducing the presence of these organisms to support symptom relief and help restore the patient's condition.

The medication is indicated for specific forms of candidiasis, which is an infection often caused by Candida species. These indications include oropharyngeal candidiasis, which affects the mouth and throat. Mycozol is also utilized in the treatment of vulvovaginal candidiasis.

The use of Mycozol in these contexts is designed to support the body's natural processes of resolution for the infection, leading to an improvement in discomfort and other associated symptoms over time.

This medication is a component of comprehensive care plans, particularly for infections that may be considered opportunistic in patients with certain underlying conditions. The goal of treatment is to support the effective management of symptoms and help improve overall quality of life.

Eligibility and Restrictions for Use

Mycozol’s use is strictly defined by regulatory eligibility rules based on its combination of active components, including Miconazole and Salicylic Acid.

Absolute Contraindications

This medicine is contraindicated for several populations. It must not be used by any patient with a known hypersensitivity or allergy to Miconazole, Thiabendazole, Salicylic Acid, Benzoic Acid, or any other ingredient in the formulation. Use is also strictly prohibited for children and teenagers who are currently experiencing viral illnesses such as influenza (flu) or varicella (chickenpox), due to the established risk of Reye's syndrome.


Age and Conditional Use Restrictions

Pediatric Use: Safety and efficacy have not been established for use in children under 2 years of age, making them ineligible for treatment.

Restricted Use in Comorbidities: Use is subject to conditional approval in patients with underlying chronic conditions. Individuals with severe renal or hepatic impairment are at risk of toxicity from systemic absorption, and therefore application is limited. Similarly, patients with diabetes mellitus or pre-existing poor circulation must exercise caution, as the topical application can increase the risk of local tissue damage or ulceration.

Pregnancy and Lactation: Use during pregnancy is restricted and should only occur if the potential benefit clearly justifies the potential risk. For women who are breastfeeding, caution is advised, and application to the breast area must be avoided.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents detail specific interaction patterns for the active ingredients in Mycozol, which are important to consider despite the product's topical application. These interactions are primarily based on the systemic potential of Miconazole and Thiabendazole.

Official Interaction Statements

Classification Type Official Regulatory Statement
Severity Contraindicated Combinations; Clinically Significant Interactions.
Basis FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).

Documented Interaction Constraints

The most significant interaction constraint relates to the pharmacokinetic interaction potential of Miconazole. Miconazole is a strong inhibitor of the enzyme CYP2C9 and an inhibitor of CYP3A4.

  • Co-administration of Miconazole is formally contraindicated with drugs that are CYP3A4 substrates and possess a narrow therapeutic index or prolong the QT interval, such as Pimozide, Quinidine, and Ergot Alkaloids.
  • The inhibition of these enzymes can lead to clinically significant increased plasma concentrations and reduced clearance of co-administered medicines, including Warfarin and certain Benzodiazepines.
  • Thiabendazole may elevate serum levels of Theophylline and can potentiate the effects of alcohol and other CNS Depressants.

These constraints define the product's interaction profile, requiring regulatory caution regarding co-administration with specific medicines, even when minimal systemic absorption is expected.

Mechanism of Action

How Mycozol Works

Mycozol (miconazole) works by employing a dual mechanistic action that targets and disrupts key components of fungal organisms at the cellular level.

Disrupting Fungal Cell Membrane Synthesis

This mechanism involves Mycozol acting as an inhibitor of the fungal enzyme cytochrome P450 14 alpha-demethylase (CYP51). This enzyme is essential for converting lanosterol into ergosterol, the primary sterol required for fungal cell membrane structure and function. The inhibition of CYP51 prevents ergosterol formation, which causes the fungal cell membrane to lose its structural integrity and become excessively permeable, initiating cellular dysfunction.

Causing Fungal Internal Oxidative Damage

The second mechanistic domain involves interference with fungal metabolic processes, specifically certain oxidase enzyme systems. This activity promotes the accumulation of toxic reactive oxygen species (ROS), such as peroxides, within the fungal cell. This high level of internal oxidative stress causes chemical damage to essential intracellular components, accelerating the loss of fungal viability and contributing to the drug's overall mechanistic effect on organism destruction.

Dosage and Administration Information

How to Use Mycozol: Administration Guidelines

Mycozol is a Topical Preparation intended exclusively for dermal application, which means it is applied externally to the skin's surface. The usage pattern for this preparation follows a standardized approach to application and duration of use based on its active components.


Application Protocol and Frequency

The standard regimen requires applying a thin layer of the preparation to sufficiently cover the entire affected area of the skin, including a small surrounding margin. Application occurs twice daily, typically once in the morning and once in the evening. The skin area to be treated should be cleaned and thoroughly dried before each application to ensure proper contact and adherence of the product.


Course Duration and Special Considerations

The typical duration of the treatment course generally ranges from two to four weeks, depending on the specific condition being addressed. The application is typically continued for at least one week after all visible signs of the infection have fully resolved. This procedural step is intended to address any remaining organisms and minimize the risk of recurrence.


Population-Specific Rules

For children aged two years and older, the same standard twice-daily application regimen is followed. However, use of the preparation in children under two years of age is performed under the supervision of a healthcare provider. No specific dose adjustment is typically required for older adults.


Handling Missed Applications

If a scheduled application is missed, the preparation should be applied as soon as the missed time is recalled, and the regular twice-daily schedule should then be resumed. Extra preparation is not applied to compensate for the missed application.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mycozol

The evidence for Mycozol, which is a combination of four active ingredients (Miconazole, Thiabendazole, Salicylic Acid, Benzoic Acid), is synthesized from studies of its individual active components and related formulations, as is common for combination products. This summary outlines the types of research and the study structures that have monitored clinical and laboratory metrics related to this type of preparation, according to authoritative scientific and regulatory sources.


Evidence for Use in Superficial Fungal Skin Conditions

Research was studied for this type of combination product in conditions where fungal infections cause the skin to become thickened or scaled, such as dermatophytosis. The evidence includes comparative clinical trials and foundational laboratory (in vitro) studies where the activity of the combined agents was evaluated. These studies monitored outcomes related to physical discomfort and mycological status (checking for fungal presence) over the course of treatment.

Research has examined the Miconazole component alongside keratolytic combinations (like Salicylic and Benzoic Acid) in these contexts. The findings from in vitro analyses described patterns observed in the studies related to fungal activity metrics when the components were used together. Trials that observed patients for several weeks reported how symptoms evolved in the studied populations. These short-term studies focusing on episodes where symptoms become more noticeable contribute to the broader evidence landscape.


Evidence for Component Use in Candida Infections

The Miconazole component was evaluated in research for candidiasis, a condition that was observed in relevant trials. For these specific indications (such as oropharyngeal and vulvovaginal candidiasis), the evidence includes a high number of Randomized Controlled Trials (RCTs) and meta-analyses that research examined Miconazole formulations against placebo or different established treatments. These trials tracked outcomes such as clinical status change and mycological status change.

However, this high-level evidence is specific to formulations designed for internal or mucosal use, such as oral gels or vaginal suppositories. Research does not describe the clinical evaluation of the external topical Mycozol preparation for these internal anatomical applications. The evidence is derived from these previously studied uses, but research does not determine whether an individual will respond similarly when using the four-ingredient combination topically.

Key Studies & References

  1. Antifungal drugs: topical (Miconazole Monograph/Guidelines)

Frequently Asked Questions (FAQ)

Common questions about Mycozol (FAQ)

Q: Can children be given Mycozol?

Official prescribing information states that the use of Mycozol is generally restricted to children aged 2 years and older. Use in children under 2 years is explicitly restricted to occur only under the supervision of a healthcare provider, according to regulatory standards.

Q: Can Mycozol be taken by people who have a liver condition?

Regulatory documents state caution is advised for individuals with severe hepatic impairment (a serious liver condition). This is because there is a potential risk of toxicity resulting from the small amount of drug that may be absorbed into the body from the skin.

Q: Is it normal to feel a mild headache when starting Mycozol?

Clinical studies involving similar Miconazole-containing formulations have reported headaches, although they are generally listed as an uncommon side effect. Official safety information primarily lists common application site reactions, but acknowledges the possibility of other uncommon effects.

Q: What happens if a dose of Mycozol is missed?

If a scheduled application is missed, the preparation should be applied as soon as the missed time is recalled, and the regular application schedule should then be resumed. Regulatory instructions explicitly advise against applying extra preparation to try and compensate for the missed one.

Q: Has Mycozol been studied in pregnant women?

Official labeling states that use of the product during pregnancy is restricted, and caution is advised. It is officially stated that the preparation should only be used if the potential benefit is considered to justify the potential risk, as described in regulatory documents.

Q: Does Mycozol have the potential to interact with alcohol?

The official product information notes that the Thiabendazole component in Mycozol may potentiate the effects of alcohol. This means official warnings exist about concurrent use with alcohol.

Q: Is it common for people to have to adjust their dose of other medicines when taking Mycozol?

Official interaction statements indicate that the Miconazole component can inhibit certain metabolic enzymes in the liver. This action can potentially lead to increased plasma concentrations of other co-administered medicines, which can raise the risk of experiencing drug-related problems.

Q: What is the official recommended age range for Mycozol use?

The eligible age range for Mycozol is defined by official safety rules. Use is not established for children under 2 years of age, and the standard treatment regimen is indicated for patients aged 2 years and older.

Q: Why do some people call Mycozol by a different name?

Mycozol is a brand name for a combination drug product containing several active ingredients, including Miconazole. It is common for patients to refer to the product by the brand name, a generic name, or the name of one of its main active components.

Q: How is Mycozol different from other medicines that treat similar conditions?

According to its pharmacological classification, Mycozol is a combination drug product. It is defined by its integrated approach, which combines an antifungal component and a keratolytic agent (which aids in shedding thickened skin), distinguishing it from simpler single-agent preparations.

Q: Does Mycozol affect birth control pills?

Official warnings exist for Miconazole formulations designed for vaginal use, as they may damage or compromise the reliability of rubber or latex contraceptive devices like condoms and diaphragms. While Mycozol is a topical skin preparation, this class-specific warning should be noted.

Q: Is Mycozol safe to use for older adults (seniors)?

Official labeling states that no specific dose adjustment is required for older adults. The product is not expected to cause different side effects or problems in this age group than it does in younger adults.

Q: Do you need a prescription to get Mycozol?

Miconazole and related combination products are frequently available as Over-the-Counter (OTC) products for specific indications in certain markets. The specific prescription status is determined by the specific formulation and the regulatory rules of the local market.

Q: Can Mycozol be used by people with a known kidney problem?

Official prescribing information advises caution for patients with severe renal impairment (a serious kidney condition). This warning is based on the potential for systemic toxicity from the components if the product is absorbed too widely or for prolonged periods.

Q: Is Mycozol generally considered a long-term or short-term treatment?

Regulatory information indicates that Mycozol is designed for a short-term treatment approach. The typical duration of a treatment course generally ranges from two to four weeks, depending on the specific condition being managed.

Q: Why is it important to know about all the medicines you are taking before starting Mycozol?

It is important because the active ingredients in Mycozol can significantly affect how other drugs are processed by the body. This interaction can increase the concentration of certain co-administered medicines, which can raise the risk of experiencing drug-related problems.

Q: Is Mycozol related to any other well-known medications?

Yes, Mycozol is a combination of four active ingredients, and its key components are used in many other well-known drug preparations. For instance, Miconazole is a widely recognized azole antifungal, and Salicylic Acid is a common keratolytic agent.

Q: Is Mycozol effective against all types of mycosis?

The product is officially intended for the treatment of most athlete’s foot, jock itch, and ringworm. The official indications limit its use to certain superficial fungal infections; it is not indicated for infections of the scalp or nails.

Q: Can Mycozol make an existing heart condition worse?

Official documents note that the Miconazole component, when absorbed systemically, has been associated with heart-related side effects such as long QT syndrome and certain arrhythmias. Regulatory caution is noted, especially regarding co-administration with other drugs that prolong the QT interval.

Q: Can I take Mycozol if I'm allergic to certain dyes or fillers?

Official labeling for products containing these components advises that patients inform their healthcare professional about any known allergies to dyes, preservatives, or non-active ingredients. Patients are advised to carefully read the full list of ingredients on the product label before use.

Q: Does Mycozol lose its effectiveness over time?

The product has a stated shelf life and must be stored at the specified Controlled Room Temperature and used before its official expiration date, in line with requirements to ensure product quality.

How should Mycozol be stored and disposed of?

The storage and disposal of Mycozol (a topical preparation) must strictly follow official regulatory requirements to ensure drug integrity and public safety.

Official Storage Requirements

  • Temperature Control: Store at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F). The product must avoid excess heat or freezing.
  • Protection: The container should be kept tightly closed in a dry place, protected from light and moisture.
  • Child Safety: It is mandatory to KEEP OUT OF REACH OF CHILDREN. If the product is swallowed, contact a Poison Control Center immediately.

Disposal

Disposal of unused or expired product must be done in accordance with local regulations. This often involves drug take-back programs. The medicine and its packaging must not be allowed to enter sewers or surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mycozol found in:

A-Z Index: